D-0387-2025 Class II Ongoing

Recalled by Breckenridge Pharmaceutical, Inc — Berlin, CT

FDA drug recall D-0387-2025 was initiated by Breckenridge Pharmaceutical, Inc on Apr 14, 2025 and is designated Class II. Reason for recall: CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit. The recall status is ongoing. Affected quantity: 16,473 bottles.

Recall details

Product Type
Drugs
Report Date
Apr 30, 2025
Initiation Date
Apr 14, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
16,473 bottles

Product description

Duloxetine Delayed-Release Capsules USP, 60 mg, 1000-count bottles, Rx Only, Manufactured by Towa Pharmaceutical Europe, S.L., Distributed by Breckenridge Pharmaceutical, Inc. Berkeley Heights, NJ 07922, NDC# 51991-748-10

Reason for recall

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Distribution pattern

US Nationwide.

Code information

Lot # 240987C, exp. date 04/2027 241014C, exp. date 04/2027

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0387-2025
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0387-2025. Report a data issue: hello@regdatalab.com.